Tumor Cell-Derived Antigens for Cancer Immunotherapy

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Lishang Xu, Yanfei Liu, Fei Liu, Qiwen Chen, Mingfeng Li, Nian Liao, Nanjiang Zheng, Xiangyu Fang, Yihao Qiu, Zhenbao Liu
{"title":"Tumor Cell-Derived Antigens for Cancer Immunotherapy","authors":"Lishang Xu,&nbsp;Yanfei Liu,&nbsp;Fei Liu,&nbsp;Qiwen Chen,&nbsp;Mingfeng Li,&nbsp;Nian Liao,&nbsp;Nanjiang Zheng,&nbsp;Xiangyu Fang,&nbsp;Yihao Qiu,&nbsp;Zhenbao Liu","doi":"10.1002/adtp.202500113","DOIUrl":null,"url":null,"abstract":"<p>Tumor vaccines have emerged as a transformative strategy in cancer immunotherapy, demonstrating substantial clinical potential. However, the genetic heterogeneity of tumor cells often leads to immune escape, limiting the effectiveness of traditional therapies that rely on a single antigen. Tumor cell-derived antigens offer a significant advantage in this regard, as they represent the unique molecular profile of the tumor, allowing for a broader and more diverse activation of the immune system. This diversity enhances the ability to overcome immune escape mechanisms, increasing the effective tumor eradication and reducing the risk of relapse. This review systematically examines two major sources of antigens: exogenous antigens, including tumor cells, tumor lysates, tumor exosomes, and tumor cell membranes, and endogenous antigens, which arise from immunogenic cell death (ICD) and possess unique advantages in eliciting strong immune activation. This work investigates synergistic therapies aimed at boosting tumor immunogenicity and counteracting the immunosuppressive microenvironment. This work reviews recent advances and challenges in tumor cell-derived antigen strategies for immune activation, emphasizing their potential to overcome limitations and facilitate the clinical translation of tumor vaccines.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 8","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://advanced.onlinelibrary.wiley.com/doi/10.1002/adtp.202500113","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Tumor vaccines have emerged as a transformative strategy in cancer immunotherapy, demonstrating substantial clinical potential. However, the genetic heterogeneity of tumor cells often leads to immune escape, limiting the effectiveness of traditional therapies that rely on a single antigen. Tumor cell-derived antigens offer a significant advantage in this regard, as they represent the unique molecular profile of the tumor, allowing for a broader and more diverse activation of the immune system. This diversity enhances the ability to overcome immune escape mechanisms, increasing the effective tumor eradication and reducing the risk of relapse. This review systematically examines two major sources of antigens: exogenous antigens, including tumor cells, tumor lysates, tumor exosomes, and tumor cell membranes, and endogenous antigens, which arise from immunogenic cell death (ICD) and possess unique advantages in eliciting strong immune activation. This work investigates synergistic therapies aimed at boosting tumor immunogenicity and counteracting the immunosuppressive microenvironment. This work reviews recent advances and challenges in tumor cell-derived antigen strategies for immune activation, emphasizing their potential to overcome limitations and facilitate the clinical translation of tumor vaccines.

Abstract Image

Abstract Image

Abstract Image

Abstract Image

肿瘤细胞源性抗原用于肿瘤免疫治疗
肿瘤疫苗已成为癌症免疫治疗的一种变革性策略,显示出巨大的临床潜力。然而,肿瘤细胞的遗传异质性经常导致免疫逃逸,限制了依赖单一抗原的传统疗法的有效性。肿瘤细胞来源的抗原在这方面提供了显著的优势,因为它们代表了肿瘤的独特分子特征,允许更广泛和更多样化的免疫系统激活。这种多样性增强了克服免疫逃逸机制的能力,增加了有效的肿瘤根除并降低了复发的风险。这篇综述系统地研究了抗原的两个主要来源:外源性抗原,包括肿瘤细胞、肿瘤裂解物、肿瘤外泌体和肿瘤细胞膜;内源性抗原,产生于免疫原性细胞死亡(ICD),在引发强烈的免疫激活方面具有独特的优势。这项工作研究了旨在增强肿瘤免疫原性和抵消免疫抑制微环境的协同疗法。这项工作回顾了肿瘤细胞源性抗原免疫激活策略的最新进展和挑战,强调了它们克服局限性和促进肿瘤疫苗临床转化的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advanced Therapeutics
Advanced Therapeutics Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
7.10
自引率
2.20%
发文量
130
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信